<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The early results (e.g., patient survival) of RFA for the treatment of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> and <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastasis</z:e> from various <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesions</z:e> including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo>, <z:hpo ids='HP_0005584'>renal cell carcinoma</z:hpo>, and <z:hpo ids='HP_0100242'>sarcoma</z:hpo> appear encouraging and suggest the potential to offer long-term survival for the patients with oligorecurrence or oligometastasis of <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The usefulness of RFA for oligorecurrence or oligometastasis of <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> should be clarified by prospective studies in the future </plain></SENT>
</text></document>